Kalayoglu Murat's Form 4 filing
Cartesian Therapeutics, Inc. (RNAC) · filed Nov 15, 2023
- Accession no.
- 0001062993-23-020921
- Filed
- Nov 15, 2023
- Trade date
- Nov 13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kalayoglu MuratCIK 0002000002 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2023 | Common Stock | AGrant or awardAcquired | +14,755,609 | –F1 | – | 14,755.61 | Direct | |
| Nov 13, 2023 | Common Stock | JOtherAcquired | +189,136,767 | –F1 | – | 189,136.77 | Indirect | |
| Nov 13, 2023 | Common Stock | PPurchaseAcquired | +619,627 | $249,999.98F4 | +$154,907,487.61 | 619.63 | Indirect | Price outlier |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F4
On November 13, 2023, the Trust entered into a Securities Purchase Agreement with the Company and other investors, pursuant to which the Trust agreed to acquire 619.627 shares of Series A Preferred Stock.
Referenced by the price of 1 transaction in Table II.